These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23116058)

  • 1. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
    Katagiri S; Umezu T; Ohyashiki JH; Ohyashiki K
    Br J Haematol; 2013 Jan; 160(2):269-71. PubMed ID: 23116058
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].
    Katagiri S; Tauchi T; Umezu T; Saito Y; Suguro T; Asano M; Yoshizawa S; Kitahara T; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Ito Y; Ohyashiki JH; Ohyashiki K
    Rinsho Ketsueki; 2015 Feb; 56(2):216-9. PubMed ID: 25765803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
    Augis V; Airiau K; Josselin M; Turcq B; Mahon FX; Belloc F
    PLoS One; 2013; 8(11):e78582. PubMed ID: 24223824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
    Valent P
    Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
    Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
    Ko TK; Chin HS; Chuah CT; Huang JW; Ng KP; Khaw SL; Huang DC; Ong ST
    Oncotarget; 2016 Jan; 7(3):2721-33. PubMed ID: 26517680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
    Carella AM
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
    [No Abstract]   [Full Text] [Related]  

  • 11. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.
    Legros L; Rousselot P; Giraudier S; Tulliez M; Huguet F; Nicolini FE; Mahon FX
    Blood; 2012 Aug; 120(9):1959-60. PubMed ID: 22936742
    [No Abstract]   [Full Text] [Related]  

  • 12. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
    Bixby D; Talpaz M
    Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective: combined forces.
    Sawyers CL
    Nature; 2013 Jun; 498(7455):S7. PubMed ID: 23803949
    [No Abstract]   [Full Text] [Related]  

  • 16. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
    Kuroda J; Puthalakath H; Cragg MS; Kelly PN; Bouillet P; Huang DC; Kimura S; Ottmann OG; Druker BJ; Villunger A; Roberts AW; Strasser A
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14907-12. PubMed ID: 16997913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching off oncogenic signals in chronic myeloid leukaemia.
    Melo J; Barnes DJ
    Hematol J; 2004; 5 Suppl 3():S183-7. PubMed ID: 15190305
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 20. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
    Mattison R; Larson RA
    Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.